Anticoagulant Use Among Members with Atrial Fibrillation and Various Pre-Existing Exlusions

    Basic Details
    Date Posted
    Friday, May 27, 2016
    Status
    Complete
    Medical Product
    anticoagulant
    dabigatran
    warfarin
    Description

    Modular program-based one-time assessment of the use of two anticoagulants, warfarin and dabigatran, among members with a pre-existing condition of atrial fibrillation and various pre-existing exclusions, including chronic liver disease, hypercholesterolemia, malignancy, coronary revascularization, other ischemic heart disease, cerebral revascularization, urinary incontinence, TIA, other cerebrovascular disease, hospitalized pneumonia, cardioversion, cardioablation, estrogen replacement, H2 antagonists, nitrates, statins, fibrates, antifungals, verapamil. The query was run against the Mini-Sentinel Distributed Database (MSDD) for the time period of October 19, 2010 to December 31, 2012.  Modular programs are adaptable standardized programs. Results were generated using Modular Program 3, version 1.0; click here for more information.  Queries were distributed in November 2013. This report includes data from 18 Data Partners.
     
    If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to info@mini-sentinel.org.
     
    The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.

    Additional Details
    FDA Center
    CDER
    Time Period
    October 19, 2010 - December 31, 2012
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    All individuals with atrial fibrillation and exclusions
    Data Sources
    Mini-Sentinel Distributed Database (MSDD)